DOCSLIB.ORG

A Abdominal Aortic Aneurysm. See Atherosclerosis Abps. See

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Abdominal Aortic Aneurysm. See Atherosclerosis Abps. See Index A metalloprotease domain, 304, 306 Abdominal aortic aneurysm. See substrates, 304, 305 Atherosclerosis and TIMP3, 304 ABPs. See Activity-based probes (ABPs) water molecule, 305 ACE. See Angiotensin-converting enzyme ADAM proteases (ACE) ADAM10 and ADAM17, 303–304 Activated neutral proteinase (ANP), 225 domain structure, 303, 304 Activity-based probes (ABPs) in vivo function, 306–307 cysteine cathepsins, 190, 191 mechanisms of activation, 311–313 human cancer tissues, 190–191 N-terminal signal sequence, 303 in vivo, 190, 191 shedding, health and disease, 308–309 metalloproteases, 191 structure, 307 MS analysis, 191 substrate recognition, 309–311 protease activity, 190 as therapeutic targets, 313 AD. See Alzheimer’s disease (AD) type I and II, 303 ADAM10, 303–304 ADAMs. See A disintegrin and ADAM and ADAM-TS proteases metalloprotease (ADAMs) amphiregulin, 503 ADAMTSs in angiogenesis adenocarcinoma cells, 444 inhibitors, 502 in arthritis, 449–450 osteoactivin, 502 3D structures in cancer, 501 CysR domain, 447–448 in inflammation and immunity Dis domain, 447 ADAM17, 504 M domain, 446–447 myeloid derived suppressor cell Sp domain, 448 (MDSC), 503 TS domain, 447 initiation, promotion and growth of tumors, endogenous inhibitors, 455–458 501–502 interglobular domain, 444 in invasion and metastasis, 503 non-catalytic domain, 448–449 as markers or therapeutic targets plasma causes, 445 ADAM17, 504 A disintegrin and metalloprotease (ADAMs) monoclonal antibody DN30, 504 in arthritis, 454–455 notch signaling, 501 3D structures TACE or tumor necrosis factor alpha CysR domain, 453 converting enzyme, 501 Dis domain, 453 ADAM17 expression EGF domain, 454 and ADAM10, 304 M domain, 452–453 K. Brix and W. Sto¨cker (eds.), Proteases: Structure and Function, 551 DOI 10.1007/978-3-7091-0885-7, © Springer-Verlag Wien 2013 552 Index A disintegrin and metalloprotease (ADAMs) eukaryotic proteases, 235 (cont.) MEROPS database, 235 endogenous inhibitors, 455–458 modular composition proteolytic cleavage, 451 BTPs, 237–238 type I transmembrane proteins, 450 C. elegans, 238 Aggrecanases. See ADAMTSs domain, 236–237 Alzheimer’s disease (AD) meprin subfamily, 237 APP, 319 pro-and catalytic domains, 238, 239 Aβ-degrading proteases N-terminal region, 242–243 ACE, 330 protein inhibitors, 246–247 IDE, 329 ovastacin, 251 MMP-2 and MMP-9, 329 zymogen structure and activation monomeric and fibrillar, 330 mechanism, 244–246 NEP and endothelin-converting Atherosclerosis enzymes, 328–329 blood vessel walls, 222 plasmin, 330 collagens and elastin, 223 β-and γ-secretase, 328 cystatin C, 223 description, 319 cysteine cathepsins, 223, 224 pathway, 319 extracellular matrix, 222 α-secretase, 320–321 GEMs, 223 β-secretase (see β-Secretase) macrophages, 223 γ-secretase, 326–328 Amyloid precursor protein (APP), 185 Angiotensin-converting enzyme (ACE), 33 B ANP. See Activated neutral proteinase (ANP) BACE1 (β-site APP cleaving enzyme), Apoptosome 322–325 cytochrome, 278–279 Blood brain barrier (BBB), 337 pro-caspase-9, 279 BMP1. See Bone morphogenetic protein protein Apaf-1, 279 1 (BMP1) APP. See Amyloid precursor protein (APP) BMP-1/tolloid-like proteases (BTPs) Arthritis cleavage sites, 247–248 ADAMs, 454–455 Drosophila tolloid, 248–249 ADAMTSs, 449–450 fibrillar procollagens, 247 cellular sources, 443 IGFBP3, 249 ECM-degrading proteinases, 443 lysyl oxidase, 249 potential candidate enzymes, 444 Bone morphogenetic protein 1 (BMP1), 236 Aspartic peptidases, 25–26 BTPs. See BMP-1/tolloid-like proteases Astacins (BTPs) active-site cleft and substrate specificity, 243–244 amphibians and fishes, 236 C BMP1, 236 CAD. See Caspase-activated DNAse (CAD) catalytic domains and metal binding sites Calpain-1/μ-calpain and calpain-2/m-calpain active-site helix, 238, 241–242 biological significance ‘cysteine-rich loop’, 241–242 brain injury, 401 polypeptide chain, 238, 239 regulation of physiological structure, 238, 240 processes, 399 zinc-binding region, 241 substrates in CNS system, 399 distribution and physiological role CNS injury, calpain-generated biomarkers BTPs, 247–249 compromised blood brain barrier crayfish astacin, 235–245, 437 (BBB), 402 hatching enzymes, 251–252 cytoskeletal structural protein human and mouse genomes, 247 aII-spectrin, 402 meprin, 249–251 CNS injury, calpain-target-based seminal fluid, 252 theranostics Index 553 acute brain injury, 402 skeletal-muscle-specific calpain, biomarkers, 403 405–409 calpain antagonists, advantage, 404 Carcinogenesis synthetic calpain inhibitors, 403 cystatin C, 220–221 theranostic approach, traumatic brain EGF-receptor, 220 injury, 404, 405 keratinocytes, 220 unique characteristics of calpain, 404 skin cancer, 220 discovery and nomenclature tumor promoters, 220 Ca 2+-activated neutral proteinase CARD. See Caspase activation and recruitment (CANP) activity, 397 domain (CARD) calpain-1 and calpain-2, 397 Cardiac homeostasis. See Cardiomyopathy calpains, isoforms, 397 Cardiomyopathy calpastatin, 398 ANP, 225 neutral proteinase (CANP) activity, 397 cathepsin L deficient mice, 224, 225 pathologic role echocardiographic investigations, 224 loss of intracellular calcium endosomal/lysosomal, 224 homeostasis, 400 macroautophagy, 224, 225 neuronal pathobiology, 400 Cardiovascular system structural features abdominal aortic aneurysm, 223–224 calpastatin, 399 cardiac homeostasis, 224–225 inactive proteases, 398 Caspase-activated DNAse (CAD), 284–285 multiple intramolecular sites, 398 Caspase activation and recruitment domain region/domains, 396, 398 (CARD), 281 Calpains in health and disease Caspases calpain-1, 395 activated initiator, 273–274 calpastatin, 395 active site architecture and substrate CAPN10 homologs recognition, 277–278 GLUT4 vesicle translocation, 415 amino acid, 275 OLETF, 415 apoptosis morphology, 286–287 conventional calpains apoptosome, 278–279 brain injury, 401 catalytic domain, 272 calpain-1/μ-calpain and calpain- catalytic mechanism, 278 2/m-calpain, 397–405 ced-3 and 4, 270–271 in disease, 401 DARP, 291–293 human calpains, structures, 396 DISC, 279–280 other calpain members diseases, 293–294 Leishmania, 416 executioner, activation, 283 Trypanosoma, 416 family members, 270 PalB homologs FLIP, 290–291 Pal-PacC and Rim pathways, 414 α-helices, 275–276 processing of PacC, 413 human, 272–273 yeasts, 413 inflammasome, 280–281 phytocalpains in keratinocytes, 274 DEK1, 416 mammalian, 272 sugarcane expressed sequence, 416 in mammals, 274 SOL homologs, 415 NC-IUBMB, 271–272 TRA-3 homologs non-mammalian and metacaspases, CAPN6 proteins, 414 274–275 mammalian CAPN6, 415 regulation and specific inhibition, 288–289 unconventional calpains Rho-ROCK signaling pathway, 287–288 gastrointestinal-tract-specific calpains, substrates 410–413 CAD, 284–285 554 Index hTERT, 285 M6P, 145–147 PARP, 285 non-lysosomal localization, 143–145 pro-interleukins and interleukins, N-terminal signal peptide, 140, 141 285–286 proteolytic processing, 142–143 ROCK 1, 284 Cathepsins tetrameric enzyme, 271 cathepsin B (see Cathepsin B) XIAP, 290 cathepsin D (see Cathepsin D) Catalytic mechanism, 23–24, 38, 180, 271, cathepsin L (see Cathepsin L) 278 cysteine (see Cysteine cathepsins) Cathepsin B in situ, 127 cancer cells, 138–139 lysosomal storage disorders, 157–158 chain enzymes, 136 M6P receptors, 128–130 disulfide bridges, 137 regulatory pathways, 127 extracellular forms, 139–140 Chain processing, cathepsin D HepG2 cells, 137 cysteine cathepsin inhibitors, 154 human tissues and cell lines, 136 double-chain processing, 154 lysosomal proteinase, 137–138 endosomal single-chain, 154 macrophages, 137 in vitro, 154 Cathepsin D psoriatic skin biopsies, 155 aspartyl proteinase, 149 Cleavage sites, PTMs biological fluids ABPs, 190–191 abnormal levels, 156 PICS, 189–190 cancer development and progression, potential protease substrates, 188 156–157 protease web, 188 mitogenic properties, 157 terminomic techniques, 188 serum/plasma, 156 test protease, 188 chain processing, 154–155 COFRADIC. See Combined fractional late endosomes, 150 diagonal chromatography maturation, 153 (COFRADIC) M6P, 149, 150 Collagenolysis non-mammalian species, 151–152 fibril-forming, 440 pH-dependent activation, 155 Hpx domain, 442 phosphotransferase, 149 mammalian collagenases, 441 proteolytic maturation, 150, 151 proteinase action, cartilage collagen fibrils, rodent biosynthesis, 150–151 441, 442 TGN, 149 triple helical structures, 441 Cathepsin L Collagen remodeling, MMPs cDNA, 140 angio-inhibitory fragments, 474 C-terminal epitope tag, 141 type I, 475–476 dimensional structures, 140 type IV, 474–475 disc electrophoretograms, 140 Colon cancer and proteases, 386–387 disulfide bridge, 140, 141 Combined fractional diagonal chromatography high-mannose carbohydrate chains, 142 (COFRADIC) IGF2R, 142 N-termini, 183–184 lysosomal proteases primary amines, 183 and carcinogenesis, 220–221 and SCX, 183 deficient mice, 219 and TNBS, 183 GEM, 219 C-termini isolation, PTMs hair follicles, 219 COFRADIC, 186, 187 keratinocytes, 219 C-TAILS, 186–187 proteolytic activity balance, 218 Cystatin B, 227–228 regular hair growth, 219 Cystatins and stefins, 102 skin barrier function, 221–222 Cysteine cathepsins Index 555 activation and maturation, 135 cysteine cathepsins aminopeptidase activity, 131 in cancer, 516 biosynthesis, 147–149 degradative processes at extra- cathepsin C, 148 lysosomal sites, 517 cathepsin H, 147 11 human cysteine cathepsins, 515 endopeptidases, 130–131 as therapeutic targets, 522–523 exopeptidolytic potential, 131 deubiquitinating enzymes or DUBs, 515 gene products, 136 IGF2R, 148 lysosomal cysteine
Load more

Recommended publications
  • Universidade Estadual De Campinas Instituto De Biologia
    UNIVERSIDADE ESTADUAL DE CAMPINAS INSTITUTO DE BIOLOGIA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA CAMPINAS 2016 1 VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA Dissertação apresentada ao Instituto de Biologia da Universidade Estadual de Campinas como parte dos requisitos exigidos para a obtenção do Título de Mestra em Biologia Funcional e Molecular na área de concentração de Bioquímica. Dissertation presented to the Institute of Biology of the University of Campinas in partial fulfillment of the requirements for the degree of Master in Functional and Molecular Biology, in the area of Biochemistry. ESTE ARQUIVO DIGITAL CORRESPONDE À VERSÃO FINAL DA DISSERTAÇÃO DEFENDIDA PELA ALUNA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA E ORIENTADA PELO DANIEL MARTINS-DE-SOUZA. Orientador: Daniel Martins-de-Souza CAMPINAS 2016 2 Agência(s) de fomento e nº(s) de processo(s): CNPq, 151787/2F2014-0 Ficha catalográfica Universidade Estadual de Campinas Biblioteca do Instituto de Biologia Mara Janaina de Oliveira - CRB 8/6972 Saia-Cereda, Verônica Aparecida Monteiro, 1988- Sa21p O proteoma do corpo caloso da esquizofrenia / Verônica Aparecida Monteiro Saia Cereda. – Campinas, SP : [s.n.], 2016. Orientador: Daniel Martins de Souza. Dissertação (mestrado) – Universidade Estadual de Campinas, Instituto de Biologia. 1. Esquizofrenia. 2. Espectrometria de massas. 3. Corpo caloso.
    [Show full text]
  • Reconstructability Analysis As a Tool for Identifying Gene-Gene Interactions in Studies of Human Diseases
    Portland State University PDXScholar Systems Science Faculty Publications and Presentations Systems Science 3-2010 Reconstructability Analysis As A Tool For Identifying Gene-Gene Interactions In Studies Of Human Diseases Stephen Shervais Eastern Washington University Patricia L. Kramer Oregon Health & Science University Shawn K. Westaway Oregon Health & Science University Nancy J. Cox University of Chicago Martin Zwick Portland State University, [email protected] Follow this and additional works at: https://pdxscholar.library.pdx.edu/sysc_fac Part of the Bioinformatics Commons, Diseases Commons, and the Genomics Commons Let us know how access to this document benefits ou.y Citation Details Shervais, S., Kramer, P. L., Westaway, S. K., Cox, N. J., & Zwick, M. (2010). Reconstructability Analysis as a Tool for Identifying Gene-Gene Interactions in Studies of Human Diseases. Statistical Applications In Genetics & Molecular Biology, 9(1), 1-25. This Article is brought to you for free and open access. It has been accepted for inclusion in Systems Science Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. Statistical Applications in Genetics and Molecular Biology Volume 9, Issue 1 2010 Article 18 Reconstructability Analysis as a Tool for Identifying Gene-Gene Interactions in Studies of Human Diseases Stephen Shervais∗ Patricia L. Kramery Shawn K. Westawayz Nancy J. Cox∗∗ Martin Zwickyy ∗Eastern Washington University, [email protected] yOregon Health & Science University, [email protected] zOregon Health & Science University, [email protected] ∗∗University of Chicago, [email protected] yyPortland State University, [email protected] Copyright c 2010 The Berkeley Electronic Press.
    [Show full text]
  • Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2010 Molecular Mechanisms Involved Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis Ryan Fassnacht Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Physiology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2246 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Ryan C. Fassnacht 2010 All Rights Reserved Molecular Mechanisms Involved in the Interaction Effects of HCV and Ethanol on Liver Cirrhosis A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University. by Ryan Christopher Fassnacht, B.S. Hampden Sydney University, 2005 M.S. Virginia Commonwealth University, 2010 Director: Valeria Mas, Ph.D., Associate Professor of Surgery and Pathology Division of Transplant Department of Surgery Virginia Commonwealth University Richmond, Virginia July 9, 2010 Acknowledgement The Author wishes to thank his family and close friends for their support. He would also like to thank the members of the molecular transplant team for their help and advice. This project would not have been possible with out the help of Dr. Valeria Mas and her endearing
    [Show full text]
  • The International Journal of Biochemistry & Cell Biology
    The International Journal of Biochemistry & Cell Biology 41 (2009) 1685–1696 Contents lists available at ScienceDirect The International Journal of Biochemistry & Cell Biology journal homepage: www.elsevier.com/locate/biocel Cathepsin X cleaves the C-terminal dipeptide of alpha- and gamma-enolase and impairs survival and neuritogenesis of neuronal cells Natasaˇ Obermajer a,b,∗, Bojan Doljak a, Polona Jamnik c,Ursaˇ Pecarˇ Fonovic´ a, Janko Kos a,b a University of Ljubljana, Faculty of Pharmacy, Askerceva 7, 1000 Ljubljana, Slovenia b Jozef Stefan Institute, Department of Biotechnology, Jamova 39, 1000 Ljubljana, Slovenia c University of Ljubljana, Biotechnical Faculty, Jamnikarjeva 101, 1000 Ljubljana, Slovenia article info abstract Article history: The cysteine carboxypeptidase cathepsin X has been recognized as an important player in degenerative Received 22 January 2009 processes during normal aging and in pathological conditions. In this study we identify isozymes alpha- Received in revised form 17 February 2009 and gamma-enolases as targets for cathepsin X. Cathepsin X sequentially cleaves C-terminal amino acids Accepted 18 February 2009 of both isozymes, abolishing their neurotrophic activity. Neuronal cell survival and neuritogenesis are, Available online 6 March 2009 in this way, regulated, as shown on pheochromocytoma cell line PC12. Inhibition of cathepsin X activity increases generation of plasmin, essential for neuronal differentiation and changes the length distribution Keywords: of neurites, especially in the early phase of neurite outgrowth. Moreover, cathepsin X inhibition increases Cathepsin X Enolase neuronal survival and reduces serum deprivation induced apoptosis, particularly in the absence of nerve Neuritogenesis growth factor. On the other hand, the proliferation of cells is decreased, indicating induction of differ- Neuronal cell survival entiation.
    [Show full text]
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • Evaluation of the Genetic Susceptibility to the Metabolic Syndrome by the CAPN10 SNP19 Gene in the Population of South Benin
    International Journal of Molecular Biology: Open Access Research Article Open Access Evaluation of the genetic susceptibility to the metabolic syndrome by the CAPN10 SNP19 gene in the population of South Benin Abstract Volume 4 Issue 6 - 2019 Metabolic syndrome is a multifactorial disorder whose etiology is resulting from the Nicodème Worou Chabi,1,2 Basile G interaction between genetic and environmental factors. Calpain 10 (CAPN10) is the first Sognigbé,1 Esther Duéguénon,1 Véronique BT gene associated with type 2 diabetes that has been identified by positional cloning with 1 1 sequencing method. This gene codes for cysteine ​​protease; ubiquitously expressed in all Tinéponanti, Arnaud N Kohonou, Victorien 2 1 tissues, it is involved in the fundamental physiopathological aspects of insulin resistance T Dougnon, Lamine Baba Moussa and insulin secretion of type 2 diabetes. The goal of this study was to evaluate the genetic 1Department of Biochemistry and Cell Biology, University of susceptibility to the metabolic syndrome by the CAPN10 gene in the population of southern Abomey-Calavi, Benin 2 Benin. This study involved apparently healthy individuals’ aged 18 to 80 in four ethnic Laboratory of Research in Applied Biology, Polytechnic School of Abomey-Calavi, University of Abomey-Calavi, Benin groups in southern Benin. It included 74 subjects with metabolic syndrome and 323 non- metabolic syndrome patients who served as controls, with 222 women versus 175 men Correspondence: Nicodème Worou Chabi, Laboratory with an average age of 40.58 ± 14.03 years old. All subjects were genotyped for the SNP of Biochemistry and Molecular Biology, Department of 19 polymorphism of the CAPN10 gene with the PCR method in order to find associations Biochemistry and Cell Biology, Faculty of Science and between this polymorphism and the metabolic syndrome.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Felipe Jun Fuzita Molecular Physiology of Digestion In
    FELIPE JUN FUZITA MOLECULAR PHYSIOLOGY OF DIGESTION IN ARACHNIDA: FUNCTIONAL AND COMPARATIVE-EVOLUTIONARY APPROACHES Thesis presented to the Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, to obtain the Title of Doctor in Biotechnology. São Paulo 2014 FELIPE JUN FUZITA MOLECULAR PHYSIOLOGY OF DIGESTION IN ARACHNIDA: FUNCTIONAL AND COMPARATIVE-EVOLUTIONARY APPROACHES Thesis presented to the Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, to obtain the Title of Doctor in Biotechnology. Concentration area: Biotechnology Advisor: Dr. Adriana Rios Lopes Rocha Corrected version. The original electronic version is available either in the library of the Institute of Biomedical Sciences and in the Digital Library of Theses and Dissertations of the University of Sao Paulo (BDTD). São Paulo 2014 DADOS DE CATALOGAÇÃO NA PUBLICAÇÃO (CIP) Serviço de Biblioteca e Informação Biomédica do Instituto de Ciências Biomédicas da Universidade de São Paulo © reprodução total Fuzita, Felipe Jun. Molecular physiology of digestion in Arachnida: functional and comparative-evolutionary approaches / Felipe Jun Fuzita. -- São Paulo, 2014. Orientador: Profa. Dra. Adriana Rios Lopes Rocha. Tese (Doutorado) – Universidade de São Paulo. Instituto de Ciências Biomédicas. Programa de Pós-Graduação Interunidades em Biotecnologia USP/IPT/Instituto Butantan. Área de concentração: Biotecnologia. Linha de pesquisa: Bioquímica, biologia molecular, espectrometria de massa. Versão do título para o português: Fisiologia molecular da digestão em Arachnida: abordagens funcional e comparativo-evolutiva. 1. Digestão 2. Aranha 3. Escorpião 4. Enzimologia 5. Proteoma 6. Transcriptoma I. Rocha, Profa. Dra. Adriana Rios Lopes I. Universidade de São Paulo. Instituto de Ciências Biomédicas. Programa de Pós-Graduação Interunidades em Biotecnologia USP/IPT/Instituto Butantan III.
    [Show full text]
  • Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes.
    [Show full text]
  • A Model for Profiling the Emolecular Effects of Alcohol
    The Pharmacogenomics Journal (2015) 15, 177–188 © 2015 Macmillan Publishers Limited All rights reserved 1470-269X/15 www.nature.com/tpj ORIGINAL ARTICLE The synaptoneurosome transcriptome: a model for profiling the emolecular effects of alcohol D Most1,2, L Ferguson1,2, Y Blednov1, RD Mayfield1 and RA Harris1 Chronic alcohol consumption changes gene expression, likely causing persistent remodeling of synaptic structures via altered translation of mRNAs within synaptic compartments of the cell. We profiled the transcriptome from synaptoneurosomes (SNs) and paired total homogenates (THs) from mouse amygdala following chronic voluntary alcohol consumption. In SN, both the number of alcohol-responsive mRNAs and the magnitude of fold-change were greater than in THs, including many GABA-related mRNAs upregulated in SNs. Furthermore, SN gene co-expression analysis revealed a highly connected network, demonstrating coordinated patterns of gene expression and highlighting alcohol-responsive biological pathways, such as long-term potentiation, long-term depression, glutamate signaling, RNA processing and upregulation of alcohol-responsive genes within neuroimmune modules. Alterations in these pathways have also been observed in the amygdala of human alcoholics. SNs offer an ideal model for detecting intricate networks of coordinated synaptic gene expression and may provide a unique system for investigating therapeutic targets for the treatment of alcoholism. The Pharmacogenomics Journal (2015) 15, 177–188; doi:10.1038/tpj.2014.43; published online 19 August 2014 INTRODUCTION mRNAs from SN15,16,18,19 and TH samples from mouse amygdala, a Alcohol dependence is a severe and widespread disease. Over 17 brain region known to be involved with the negative reinforce- 20 million Americans suffer from alcohol-related problems; total cost ment of alcohol and other drugs of abuse.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Calpain-10 Regulates Actin Dynamics by Proteolysis of Microtubule-Associated Protein 1B
    www.nature.com/scientificreports OPEN Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B Received: 15 September 2015 Tomohisa Hatta1, Shun-ichiro Iemura1,6, Tomokazu Ohishi2, Hiroshi Nakayama3, Accepted: 1 November 2018 Hiroyuki Seimiya 2, Takao Yasuda4, Katsumi Iizuka5, Mitsunori Fukuda4, Jun Takeda5, Published: xx xx xxxx Tohru Natsume1 & Yukio Horikawa5 Calpain-10 (CAPN10) is the calpain family protease identifed as the frst candidate susceptibility gene for type 2 diabetes mellitus (T2DM). However, the detailed molecular mechanism has not yet been elucidated. Here we report that CAPN10 processes microtubule associated protein 1 (MAP1) family proteins into heavy and light chains and regulates their binding activities to microtubules and actin flaments. Immunofuorescent analysis of Capn10−/− mouse embryonic fbroblasts shows that MAP1B, a member of the MAP1 family of proteins, is localized at actin flaments rather than at microtubules. Furthermore, fuorescence recovery after photo-bleaching analysis shows that calpain-10 regulates actin dynamics via MAP1B cleavage. Moreover, in pancreatic islets from CAPN10 knockout mice, insulin secretion was signifcantly increased both at the high and low glucose levels. These fndings indicate that defciency of calpain-10 expression may afect insulin secretion by abnormal actin reorganization, coordination and dynamics through MAP1 family processing. Calpains are a family of intracellular non-lysosomal calcium-activated neutral cysteine proteases known to cleave various substrate proteins and modulate their activities. Tere are 16 calpains, some of which are ubiquitously expressed and others displaying tissue-specifc distribution. Some calpains contain a penta-EF-hand domain (typical or classical calpains), and others do not (atypical calpains). Several calpain family members are impli- cated in the development of various diseases including Alzheimer’s disease, cataracts, ischemic stroke, traumatic brain injury, limb-girdle muscular dystrophy 2A and type 2 diabetes mellitus (T2DM)1.
    [Show full text]